Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company's solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Instruments & Supplies
- Sub-Industry: N/A
- Symbol: NASDAQ:TRIV
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $6.49
- 200 Day Moving Avg: $6.07
- 52 Week Range: $3.98 - $11.49
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.16
- P/E Growth: 0.00
- Average Volume: 17,155 shs.
Frequently Asked Questions for Trivascular Technologies (NASDAQ:TRIV)
What is Trivascular Technologies' stock symbol?
Trivascular Technologies trades on the NASDAQ under the ticker symbol "TRIV."
How were Trivascular Technologies' earnings last quarter?
Trivascular Technologies Inc (NASDAQ:TRIV) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.05. The company earned $9.50 million during the quarter, compared to analyst estimates of $9.28 million. Trivascular Technologies's quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.69) EPS. View Trivascular Technologies' Earnings History.
Who are some of Trivascular Technologies' key competitors?
Some companies that are related to Trivascular Technologies include Becton Dickinson and Co (BDX), Baxter International (BAX), C R Bard (BCR), Mettler-Toledo International (MTD), DENTSPLY SIRONA (XRAY), Waters (WAT), Cooper Companies (COO), Teleflex Incorporated (TFX), West Pharmaceutical Services (WST), Hill-Rom Holdings (HRC), Integra Lifesciences Holdings Corp (IART), ProShares UltraShort DJ-UBS Commodity (CMD), ICU Medical, Incorporated (ICUI), Insulet (PODD), Haemonetics (HAE), Inogen (INGN), Merit Medical Systems (MMSI) and Halyard Health (HYH).
How do I buy Trivascular Technologies stock?
Shares of Trivascular Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trivascular Technologies' stock price today?
MarketBeat Community Rating for Trivascular Technologies (NASDAQ TRIV)MarketBeat's community ratings are surveys of what our community members think about Trivascular Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Trivascular Technologies stock can currently be purchased for approximately $5.87.
Earnings History for Trivascular Technologies (NASDAQ:TRIV)Earnings History by Quarter for Trivascular Technologies (NASDAQ:TRIV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2015||Q3||($0.71)||($0.66)||$9.28 million||$9.50 million||View||N/A|
|8/4/2015||Q215||($0.73)||($0.73)||$8.78 million||$9.70 million||View||N/A|
|5/5/2015||Q115||($0.68)||($0.77)||$8.48 million||$9.00 million||View||Listen|
|3/3/2015||Q414||($0.65)||($0.72)||$9.54 million||$9.10 million||View||Listen|
|11/10/2014||Q314||($0.63)||($0.69)||$7.90 million||$7.88 million||View||N/A|
|8/6/2014||Q214||($0.66)||($0.87)||$7.54 million||$7.80 million||View||N/A|
|5/14/2014||Q1 14||($1.10)||($1.17)||$6.90 million||$7.00 million||View||N/A|
Earnings Estimates for Trivascular Technologies (NASDAQ:TRIV)
Current Year EPS Consensus Estimate: $-2.84 EPS
Next Year EPS Consensus Estimate: $-2.72 EPS
Dividend History for Trivascular Technologies (NASDAQ:TRIV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Trivascular Technologies (NASDAQ:TRIV)Insider Trades by Quarter for Trivascular Technologies (NASDAQ:TRIV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/22/2014||Douglas A Roeder||Director||Buy||833,333||$12.00||$9,999,996.00|| |
|4/22/2014||Enterprise Associates 12 New||Major Shareholder||Buy||583,333||$12.00||$6,999,996.00|| |
|4/22/2014||James E Flynn||Insider||Buy||1,065,000||$12.01||$12,790,650.00|| |
Headline Trends for Trivascular Technologies (NASDAQ:TRIV)
Latest Headlines for Trivascular Technologies (NASDAQ:TRIV)
|TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acqu|
biz.yahoo.com - February 3 at 5:23 PM
|TriVascular Technologies, Inc. (TRIV)|
biz.yahoo.com - January 17 at 7:47 PM
|TRIVASCULAR TECHNOLOGIES, INC. Financials|
finance.yahoo.com - December 8 at 1:17 PM
|TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement|
biz.yahoo.com - November 9 at 4:21 PM
|Q3 2015 TriVascular Technologies Inc Earnings Release - After Market Close|
biz.yahoo.com - November 9 at 7:07 AM
|Preliminary Results of the LIFE Study Presented at VIVA 2015|
finance.yahoo.com - November 3 at 12:45 PM
|Four-Year Results From Global Ovation Pivotal Trial Presented at VIVA 2015|
finance.yahoo.com - November 3 at 12:30 PM
|TRIV SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of TriVascular Technologies, Inc. Regarding the Sale of the Company to Endologix, Inc.|
finance.yahoo.com - November 2 at 12:01 PM
|SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of TriVascular Technologies, Inc. -TRIV|
finance.yahoo.com - October 30 at 9:45 PM
|INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of TriVascular Technologies, Inc. of an Investigation Concerning the Fairness of the Sale of the Company to Endologix, Inc.|
finance.yahoo.com - October 30 at 11:04 AM
|INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of TriVascular Technologies, Inc. And Encourages Investors To Contact The Firm For Additional Information|
finance.yahoo.com - October 29 at 5:25 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of TriVascular Technologies, Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Endologix, Inc. - TRIV|
finance.yahoo.com - October 29 at 2:29 PM
Trivascular Technologies (TRIV) Chart for Monday, May, 29, 2017